Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAK683 phase I/II study in advanced malignancies
NL-OMON46802Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of MAK683 in lymphoma and Nonhematologic neoplasms (2 arms), sponsored by Novartis. Primary endpoints: Dose-limiting toxicities, Adverse events and serious adverse events and 2 more. Planned start Jan 2018; status: withdrawn.
02
Drugs
MAK683
03
Conditions
lymphomaNonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON46802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46802.